Henry Ford Health System
Illumina, Henry Ford Health Partner on Genomic Testing for Cardiovascular Patients
The partnership could yield data to support the use of whole-genome sequencing in treating and managing cardiovascular disease, the leading cause of death in the US.
Polygenic Risk Score Shows Promise Predicting Beta Blocker Response in Heart Failure Patients
Premium
Researchers from Henry Ford Health in Detroit hope to prospectively validate the pharmacogenomics PRS's ability to predict survival benefit for patients on beta blockers.
With nearly $100 million in new investments since last year, the San Francisco-based informatics firm looks to ramp up its precision oncology partnerships.
The Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) clinical trial is enrolling its first patients.